Get the Stockscreener App
136.31
1.27%
1.715
Ascendis Pharma A S Adr Stock (ASND) Latest News
European Equities Traded in the US as American Depositary Receipts Trend Lower in Tuesday Trading - MSN
European Equities Traded in the US as American Depositary Receipts Decline in Thursday Trading - MSN
European Equities Traded in the US as American Depositary Drop in Friday Trading, Down 2.8% for Week - MSN
European Equities Traded in the US as American Depositary Rise in Monday Trading - MSN
European Equities Traded in the US as American Depositary Move Higher in Monday Trading - MSN
Wegovy Manufacturer Inks Multi-Million Deal For Monthly Obesity Drug - Benzinga
TD Cowen boosts Ascendis stock target, sees Q3 Skytrofa growth lagging but long-term outlook intact - Investing.com
Nothing is Better Than Ascendis Pharma A/S ADR (ASND) stock at the moment - SETE News
Financial Health Report: Ascendis Pharma A/S ADR (ASND)’s Ratios Tell a Tale - The Dwinnex
Ascendis Pharma A/S ADR’s Banking’s 100-Day Moving Average at 134.03: Will the Stock Break Through? - The InvestChronicle
Stock Market Recap: Ascendis Pharma A/S ADR (ASND) Concludes at 132.05, a -5.10 Surge/Decline - The Dwinnex
The Ascendis Pharma A/S ADR (ASND) had a good session last reading, didn’t it? - US Post News
Stocks Showing Rising Market Leadership: Ascendis Pharma ADR Earns 83 RS Rating - Investor's Business Daily
Top investors say Ascendis Pharma A/S ADR (ASND) ticks everything they need - SETE News
Ascendis reports positive 3-year hypoparathyroidism trial data - Investing.com
Results from Ascendis Pharma A/S ADR (ASND) show risk - US Post News
Sei Investments Co. Sells 81,615 Shares of Ascendis Pharma A/S (NASDAQ:ASND) - MarketBeat
Ascendis Pharma A/S (NASDAQ:ASND) Price Target Raised to $191.00 - MarketBeat
Ascendis Pharma A/S (NASDAQ:ASND) Holdings Lifted by Evolutionary Tree Capital Management LLC - MarketBeat
European Equities Traded in the US as American Depositary Receipts Edge Lower in Tuesday Trading - MSN
Investor’s Delight: Ascendis Pharma A/S ADR (ASND) Closes Strong at 148.88, Up 1.56 - The Dwinnex
Ascendis Pharma launches $300 million public offering - Investing.com
Ascendis Pharma A/S (NASDAQ:ASND) Shares Acquired by Seven Eight Capital LP - MarketBeat
Analysts review Ascendis Pharma A/S ADR’s rating - Knox Daily
Ascendis Pharma A/S Announces Proposed Public Offering of ADSs - Yahoo Finance
Analyzing Edgewise Therapeutics Inc (EWTX) After Recent Trading Activity - Knox Daily
Ascendis Pharma A/S ADR (ASND) did well last session? - US Post News
Ascendis Pharma shares retain Outperform rating, Evercore ISI lifts target citing potential in new patient starts - Investing.com
Prepare Yourself for Liftoff: Ascendis Pharma A/S ADR (ASND) - SETE News
Oppenheimer raises Ascendis Pharma shares, maintains Outperform rating - Investing.com India
Goldman Sachs raises Ascendis Pharma stock price target on study success - Investing.com India
Jefferies lifts Ascendis Pharma target to $179 on trial data - Investing.com
Barclays maintains BioMarin at Overweight with $110 target - Investing.com
Why This Small Biotech Is Hammering BioMarin Today - Investor's Business Daily
Positive topline data supports Ascendis Pharma stock, analyst highlights potential for weekly injection advantage. - Investing.com India
Ascendis Pharma reaffirms stock target, buy rating on study success - Investing.com
Ascendis Pharma reports growth in achondroplasia trial - Investing.com India
Citi maintains buy on Ascendis with $178 target amid trial data - Investing.com
Market Insights: Ascendis Pharma A/S ADR (ASND)’s Notable Gain of 0.78, Closing at 113.81 - The Dwinnex
Ascendis Pharma A/S ADR (ASND)’s highs and lows: A closer look at its stock price fluctuations - US Post News
Closing Figures Unveiled: Ascendis Pharma A/S ADR (ASND) Drop -1.94, Closes at 116.84 - The Dwinnex
Citi maintains Ascendis Pharma stock at Buy, positive outlook ahead of pivotal trial data - Investing.com India
A better buy-in window may exist right now for Ascendis Pharma A/S ADR (ASND) - SETE News
European Equities Traded in the US as American Depositary Receipts Flat in Monday Trading - MSN
TD Cowen maintains Buy on Ascendis, keeps $157 target - Investing.com
Ascendis Pharma A/S ADR (ASND) requires closer examination - US Post News
Stock Performance Spotlight: Ascendis Pharma A/S ADR (ASND) Ends the Day at 119.50, Down by -11.27 - The Dwinnex
Jefferies cuts Ascendis share price target amid hGH market pressure - Investing.com
Goldman Sachs cuts Ascendis Pharma shares target, maintains Buy rating - Investing.com
Ascendis Pharma stock target cut, retains rating amid Skytrofa sales miss - Investing.com
Earnings call: Ascendis Pharma reports mixed Q2 2024 results, forecasts growth - Investing.com
Biotech Makes A Bearish Move On Drug-Pricing Fiasco - Investor's Business Daily
Taking on analysts’ expectations and winning: Ascendis Pharma A/S ADR (ASND) - SETE News
Ascendis Pharma stock tanks on earnings miss - Investing.com
Ascendis Pharma A/S ADR (ASND) Stock: A Year of Stock Market Ups and Downs - The InvestChronicle
Ascendis Pharma A/S ADR (ASND) Stock: Navigating a Year of Volatility - The InvestChronicle
JPMorgan raises Ascendis Pharma stock target on drug approval - Investing.com
Can you still get a good price for Ascendis Pharma A/S ADR (ASND) Shares at this point? - US Post News
Market Watch: Ascendis Pharma A/S ADR (ASND)’s Noteworthy Drop, Closing at 139.50 - The Dwinnex
1.35%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):